FDA Approves Amgen's AMJEVITA ™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases

First Regulatory Approval for Company's Biosimilar Portfolio First Biosimilar Adalimumab Approved by FDA THOUSAND OAKS, Calif., Sept. 23, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA™ (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaqu...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news